Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTH258 vs aflibercept in neovascular age-related macular degeneration
2014-004886-26Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2015
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab in exudative macular degeneration (2 arms), sponsored by Alcon Inc. Primary endpoint: Change in best-corrected visual acuity from baseline to week 48. Started Jun 2015; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2014-004886-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004886-26.